← FDA Drug Approvals (Drugs@FDA)
ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: LAURUS LABS LTD · Approved 2022-08-11
Drug application
- FDA Application #
ANDA216223- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE
- Generic name
- Abacavir
- Active ingredients
- ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- None (Tentative Approval)
- Sponsor
- LAURUS LABS LTD
- First approval
- 2022-08-11
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown